{
 "ticker": "GNMX",
 "name": "Corgi Genomics & Precision Medicine ETF",
 "issuer": "Corgi",
 "desk": "themes",
 "url": "https://etfiq.com/funds/gnmx",
 "html": "https://etfiq.com/funds/gnmx",
 "markdown": "https://etfiq.com/funds/gnmx.md",
 "as_of": "2026-09-18",
 "verdict": "GNMX holds 58 stocks, and 73% of its weight is outside the S&P 500.",
 "key_facts": [
  {
   "key": "already_in_the_s_p_500",
   "label": "Already in the S&P 500",
   "value": "26.7%",
   "source": null,
   "as_of": "2026-09-18",
   "sentence": "GNMX, already in the S&P 500: 26.7%, as of Sep 18, 2026."
  },
  {
   "key": "active_share_vs_the_s_p_500",
   "label": "Active share vs the S&P 500",
   "value": "99.4%",
   "source": null,
   "as_of": "2026-09-18",
   "sentence": "GNMX, active share vs the S&P 500: 99.4%, as of Sep 18, 2026."
  },
  {
   "key": "top_ten_holdings",
   "label": "Top ten holdings",
   "value": "45.1%",
   "source": null,
   "as_of": "2026-09-18",
   "sentence": "GNMX, top ten holdings: 45.1%, as of Sep 18, 2026."
  },
  {
   "key": "total_return_since_launch",
   "label": "Total return, since launch",
   "value": "+41.2%",
   "source": null,
   "as_of": "2026-09-18",
   "sentence": "GNMX, total return, since launch: +41.2%, as of Sep 18, 2026."
  },
  {
   "key": "net_assets",
   "label": "Net assets",
   "value": "$3m",
   "source": "the issuer\u2019s own daily fund list, as of Sep 18, 2026",
   "as_of": "2026-09-18",
   "sentence": "GNMX, net assets: $3m (the issuer\u2019s own daily fund list, as of Sep 18, 2026)."
  },
  {
   "key": "expense_ratio",
   "label": "Expense ratio",
   "value": "0.35%",
   "source": "485BPOS XBRL, Apr 30, 2026",
   "as_of": "2026-09-18",
   "sentence": "GNMX, expense ratio: 0.35% (485BPOS XBRL, Apr 30, 2026)."
  }
 ],
 "fields": [
  {
   "key": "theme",
   "label": "Theme",
   "value": "Genomics and gene editing",
   "source": "ETFIQ, editorial"
  },
  {
   "key": "launched",
   "label": "Launched",
   "value": "May 6, 2026",
   "source": null
  },
  {
   "key": "already_in_the_s_p_500_by_weight",
   "label": "Already in the S&P 500, by weight",
   "value": "26.7%",
   "source": "ETFIQ"
  },
  {
   "key": "active_share_vs_the_s_p_500",
   "label": "Active share vs the S&P 500",
   "value": "99.4%",
   "source": "ETFIQ"
  },
  {
   "key": "already_in_the_nasdaq_100_by_weight",
   "label": "Already in the Nasdaq-100, by weight",
   "value": "8.5%",
   "source": "ETFIQ"
  },
  {
   "key": "active_share_vs_the_nasdaq_100",
   "label": "Active share vs the Nasdaq-100",
   "value": "99.3%",
   "source": "ETFIQ"
  },
  {
   "key": "top_ten_holdings_weight",
   "label": "Top ten holdings weight",
   "value": "45.1%",
   "source": null
  },
  {
   "key": "holdings",
   "label": "Holdings",
   "value": "58",
   "source": null
  },
  {
   "key": "holdings_published_for",
   "label": "Holdings published for",
   "value": "Sep 18, 2026",
   "source": "the issuer\u2019s daily file"
  },
  {
   "key": "top_holdings",
   "label": "Top holdings",
   "value": "Thermo Fisher Scientific Inc 8.6%, Moderna Inc 7.0%, Vertex Pharmaceuticals Inc 5.9%, Illumina Inc 4.4%, Guardant Health Inc 3.9%, 10X Genomics Inc 3.4%, Revolution Medicines Inc 3.3%, Genmab A/S 2.9%, Incyte Corp 2.9%, Twist Bioscience Corp 2.9%",
   "source": null
  },
  {
   "key": "net_assets",
   "label": "Net assets",
   "value": "$3m",
   "source": "the issuer\u2019s own daily fund list, as of Sep 18, 2026"
  },
  {
   "key": "below_its_all_time_high",
   "label": "Below its all-time high",
   "value": "\u22121.0%",
   "source": "ETFIQ"
  },
  {
   "key": "expense_ratio",
   "label": "Expense ratio",
   "value": "0.35%",
   "source": "485BPOS XBRL, Apr 30, 2026"
  },
  {
   "key": "fee_for_the_part_that_differs_from_the_s_p_500_active_expense_ratio",
   "label": "Fee for the part that differs from the S&P 500, active expense ratio",
   "value": "0.35%",
   "source": "ETFIQ"
  },
  {
   "key": "closest_funds_by_holdings_overlap",
   "label": "Closest funds by holdings overlap",
   "value": "GNOM 47%, HLTH 36%, ARKG 35%, WDNA 32%, IDNA 31%",
   "source": null
  }
 ],
 "periods": [
  {
   "window": "3 months",
   "Total return": "+29.7%",
   "S&P 500": "+2.3%",
   "Gap to S&P 500": "+27.4 pts",
   "Gap to Nasdaq-100": "+32.2 pts"
  },
  {
   "window": "Since launch",
   "Total return": "+41.2%",
   "S&P 500": "+4.3%",
   "Gap to S&P 500": "+36.9 pts",
   "Gap to Nasdaq-100": "+37.4 pts"
  }
 ],
 "questions": [
  {
   "q": "How much of GNMX is in S&P 500 companies?",
   "a": "By its holdings published by its issuer for Sep 18, 2026, 27% of GNMX by weight is stocks the S&P 500 already holds. Its active share against the index is 99%, so that share is the part doing something different."
  },
  {
   "q": "What does GNMX hold?",
   "a": "58 positions as published by its issuer for Sep 18, 2026, with the top ten at 45% of the fund. The largest are Thermo Fisher Scientific Inc at 8.6%, Moderna Inc at 7.0%, Vertex Pharmaceuticals Inc at 5.9%."
  },
  {
   "q": "Has GNMX beaten the S&P 500?",
   "a": "Over the year to Sep 18, 2026 GNMX returned +41.2% with distributions reinvested, against +4.3% for the S&P 500, so it finished ahead of the index by 36.9 points."
  },
  {
   "q": "What does GNMX cost?",
   "a": "The prospectus expense ratio is 0.35% a year. Because 99% of the fund differs from the S&P 500, the fee on that differing part works out at 0.35%."
  }
 ],
 "generated": "2026-09-21",
 "license": "Free to use with attribution. ETFIQ (etfiq.com)."
}